In today’s ACT Brief, we examine how fragmented data collection continues to challenge trial quality, how hybrid outsourcing ...

Jonathan Andrus, co-CEO of CRIO, discusses how increased reliance on site-based technologies and eSource is strengthening ...

In today’s ACT Brief, we explore how sites are taking the lead on AI adoption to strengthen feasibility and enrollment, why earlier cross-functional alignment is critical in data-driven trials, and ...

Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving consistency, oversight, and efficiency across clinical trial sites.

Andrus: The biggest risk is fragmented, disconnected data collection across sites. If you think about a large phase 3 trial ...

Jonathan Andrus, co-CEO of CRIO, discusses how governance across the data lifecycle, site-focused technology adoption, and scalable AI-enabled workflows will define operational readiness in 2026.

In today’s ACT Brief, we examine how protocol-driven eSource is reshaping data capture at sites, how digital protocols and ...

At SCOPE Summit 2026, site leaders shared how AI is transforming feasibility, patient identification, and enrollment strategies, enabling research sites to boost performance, strengthen sponsor ...

In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo ...

Angela Zubel, chief development officer, Debiopharm, discusses why 2026 marks a shift from AI pilots to broader operational ...

Mayo Clinic, for its part, described the collaboration as its first strategic partnership of this scale with a global ...

Angela Zubel, chief development officer, Debiopharm, explains how AI-enabled site selection, patient allocation, and real-time data monitoring can reduce costs, shorten timelines, and limit ...